BEAM Beam Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745999 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.3%
TTM net income YoY74.1%
TTM EPS YoY80.0%
Revenue 3-yr CAGR21.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-267.7%
Net margin-73.0%
FCF margin-271.6%
EBITDA margin-252.6%
Returns
ROE-11.1%
ROA-8.3%
ROIC (approx.)-40.2%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets24.9%
Debt / equity0.11x
Current ratio13.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.63x
Accruals ratio21.8%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $307,000 | $490,000 | $31.74M | $114.11M | $9.70M | $8.47M | $7.47M | $30.07M |
| R&D expense | $110.11M | $95.10M | $104.52M | $99.28M | $109.77M | $101.76M | $98.82M | $101.44M |
| SG&A expense | $31.52M | $31.95M | $34.43M | $32.28M | $26.74M | $26.86M | $27.94M | $28.66M |
| Operating income | -$141.32M | -$126.55M | -$107.22M | -$17.45M | -$126.81M | -$120.15M | -$119.29M | -$100.04M |
| Pretax income | — | — | — | $244.30M | -$112.73M | -$102.29M | — | -$90.35M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$134.41M | -$122.68M | -$94.32M | $244.30M | -$112.57M | -$102.14M | -$108.33M | -$90.35M |
| EBITDA | -$135.88M | -$121.14M | -$101.61M | -$11.78M | -$121.25M | -$114.61M | -$113.76M | -$94.59M |
| EPS (basic) | -1.28 | -1.18 | -0.91 | — | -1.10 | -1.00 | -1.23 | — |
| EPS (diluted) | -1.28 | -1.18 | -0.91 | — | -1.10 | -1.00 | -1.23 | — |
| Weighted avg. shares (diluted) | 104.70M | 104.33M | 103.26M | — | 102.57M | 102.00M | 87.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $213.27M | $219.82M | $288.29M | $294.94M | $267.96M | $282.13M | $527.91M | $290.11M |
| Short-term investments | $830.61M | $933.10M | $923.36M | $950.27M | $807.01M | $868.21M | $692.04M | $568.77M |
| Current assets | $1.07B | $1.18B | $1.27B | $1.27B | $1.10B | $1.18B | $1.25B | $878.15M |
| PP&E, net | $94.04M | $97.61M | $101.25M | $104.50M | $108.29M | $108.82M | $109.57M | $111.41M |
| Total assets | $1.27B | $1.39B | $1.48B | $1.48B | $1.31B | $1.39B | $1.47B | $1.10B |
| Current liabilities | $82.08M | $80.88M | $74.56M | $96.94M | $182.56M | $174.13M | $141.55M | $182.07M |
| Long-term debt | $100.36M | $100.26M | $100.19M | — | — | — | — | — |
| Total debt | $100.36M | $100.26M | $100.19M | — | — | — | — | — |
| Total liabilities | $316.40M | $318.91M | $316.36M | $242.82M | $345.08M | $344.34M | $343.78M | $370.28M |
| Shareholders' equity | $952.67M | $1.07B | $1.16B | $1.24B | $972.66M | $1.05B | $1.13B | $733.54M |
| Net debt | -$112.90M | -$119.57M | -$188.10M | — | — | — | — | — |
| Shares outstanding | 103.44M | 103.26M | 102.74M | 101.75M | 101.36M | 100.76M | 100.56M | 83.63M |
| Cash flow statement | ||||||||
| Operating cash flow | -$110.75M | -$66.10M | -$128.51M | -$83.29M | -$81.48M | -$76.45M | -$103.88M | -$76.36M |
| Capital expenditure | $1.21M | $2.41M | $2.23M | $3.73M | $5.01M | $3.14M | $3.06M | $2.97M |
| Free cash flow | -$111.96M | -$68.51M | -$130.75M | -$87.02M | -$86.49M | -$79.59M | -$106.95M | -$79.33M |
| Investing cash flow | $101.86M | -$9.88M | $25.27M | $108.41M | $65.66M | -$170.41M | -$125.09M | $126.28M |
| Financing cash flow | $2.33M | $7.52M | $96.61M | $1.89M | $1.68M | $1.11M | $473.38M | $3.44M |
| Depreciation & amortization | $5.45M | $5.41M | $5.61M | $5.67M | $5.56M | $5.54M | $5.53M | $5.44M |
| Stock-based compensation | $18.55M | $19.28M | $19.04M | $20.45M | $22.75M | $24.37M | $26.68M | $30.22M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.